The benefit of adding oxaliplatin to adjuvant
fluoropyrimidine chemotherapy in patients >70 years is controversial. This
retrospective audit investigated usage, benefit and tolerability of adjuvant
chemotherapy for colon cancer in older adults. Materials and methods: Patients
aged >60 years with stage III colon cancer referred for adjuvant
chemotherapy between 2010–2012 were identified from a tertiary hospital
oncology database.
Data were collected on demographics,
chemotherapy received, completion rates, toxicities, relapse and survival.
Comparison was made between the older group (age >70 years) and the younger
group (age 60-70 years). Results: 95 eligible patients were identified; 50 in
the older group (median age 76), 45 in the younger group (median age 66), 56%
male, 82% NZ European and 5% Maori.
Older patients were less likely to receive
adjuvant chemotherapy (76% and 91% in the older and younger group respectively,
p=0.0017), especially oxaliplatincontaining regimens (14% and 47% of older and
younger groups, respectively). Similar proportions in each group completed
>80% of planned chemotherapy doses with no significant difference in early
discontinuation due to toxicities.
No comments:
Post a Comment